Share chart Tricida, Inc.
Extended chart
Simple chart
About Tricida, Inc.
Фармацевтическая компания Tricida, Inc. сосредоточена на разработке и коммерциализации своего препарата-кандидата TRC101, не абсорбируемого перорального полимера, предназначенного для потенциального лечения метаболического ацидоза у пациентов с хронической болезнью почек (ХБП). Компания завершила фазу 3, двойное слепое плацебо-контролируемое исследование TRC101 у пациентов с ХБП и метаболическим ацидозом. Компания Tricida, Inc. была основана в 2013 году со штаб-квартирой в Южном Сан-Франциско, штат Калифорния.Main settings
IPO date
2018-06-28
ISIN
US89610F1012
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0 | 0 |
| P/BV | -0.006 | 0 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -102.07 | 0 |
| ROE | 197.1 | 10 |
| ROIC | -68.96 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -1.68 | 10 |
| Debt/Ratio | 2.22 | 6 |
| Debt/Equity | -1.69 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 20.94 | 4 |
| Yield EPS, % | -50.22 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 0.0141 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 0.0141 $ | 0.0141 $ | 0.0141 $ | 0 % | 0 % | 0 % |
| Month | 0.0141 $ | 0.0141 $ | 0.0141 $ | 0 % | 0 % | 0 % |
| Three month | 0.0141 $ | 0.0141 $ | 0.0141 $ | 0 % | 0 % | 0 % |
| Half a year | 0.0141 $ | 0.0141 $ | 0.0141 $ | 0 % | 0 % | 0 % |
| Year | 0.0141 $ | 0.0141 $ | 0.0141 $ | 0 % | 0 % | 0 % |
| 3 years | 12.39 $ | 0.0125 $ | 13.6 $ | -99.89 % | 0 % | 0 % |
| 5 years | 14.18 $ | 0.0125 $ | 27.22 $ | -99.9 % | 0 % | 0 % |
| 10 years | 0 $ | 0.0125 $ | 43.71 $ | 0 % | 0 % | 0 % |
| Year to date | 0.0141 $ | 0.0141 $ | 0.0141 $ | 0 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Orbimed Advisors LLC. | 10 280 947 | 18.47 |
| VR Adviser, LLC | 9 050 064 | 16.26 |
| Blackrock Inc. | 3 698 400 | 6.64 |
| Frazier Life Sciences Management, L.P. | 2 549 671 | 4.58 |
| Commodore Capital, LP | 1 975 403 | 3.55 |
| Vanguard Group, Inc. (The) | 1 661 860 | 2.99 |
| Lion Point Capital, LP | 1 367 597 | 2.46 |
| Baker Brothers Advisors, LLC | 1 320 290 | 2.37 |
| Stonehill Capital Management LLC | 1 198 443 | 2.15 |
| Deep Track Capital, LP | 1 177 680 | 2.12 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Geoffrey M. Parker | COO, CFO & Exec. VP | 656.28k | 1964 (61 year) |
| Mr. Robert L. McKague J.D. | Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer | 570.51k | |
| Dr. Dawn Parsell Ph.D. | Exec. VP of Clinical Devel. | 649.17k | 1962 (63 years) |
| Ms. Annie Yoshiyama | VP of Fin. & Chief Accounting Officer | N/A | 1983 (42 years) |
| Jackie Cossmon | VP of Investor Relations & Communications | N/A | |
| Mr. Edward J. Hejlek Esq., J.D. | Exec. VP of Intellectual Property | N/A | 1956 (69 years) |
| Dr. Gerrit Klaerner Ph.D. | Founder, Pres, CEO & Exec. Director | 992.55k | 1972 (53 years) |
About company
Address: United States, South San Francisco, 7000 Shoreline Court - Open in google maps, Open in yandex maps
Website: http://www.tricida.com
Website: http://www.tricida.com
